Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks

The Conference Board Consumer Confidence Index fell 6.7% to 81.9 in September, its lowest level since April 2014 and well below the 89.2 consensus forecast, while the share of consumers viewing jobs as plentiful declined to 23.6%. Rising oil prices tied to the U.S.-Iran conflict have lifted inflation, prompting a 25bp Federal Reserve rate hike and signaling risk of another increase this year. The article recommends defensive healthcare and consumer-staples exposure, highlighting BHC, CDNA, DOLE and CHEF based on improving earnings estimates and projected current-year earnings growth.

Analysis

The proposed basket is not uniformly defensive. BHC has relatively recurring prescription demand, but its equity remains highly sensitive to leverage, refinancing costs and any delay in deleveraging; a higher-for-longer rate regime can offset the usual healthcare-demand benefit. CDNA is an idiosyncratic reimbursement, utilization and regulatory story rather than a macro hedge, while CHEF has meaningful exposure to discretionary fine-dining, hospitality and independent-restaurant traffic—precisely where a weakening labor backdrop can pressure volumes and customer credit.

DOLE is lower beta, but fresh-produce margins are vulnerable to fuel, freight, packaging and labor inflation; it can defend volume better than price/margin if consumers trade down. The cleaner second-order expression is a widening relative-performance gap between staples and discretionary/restaurants: XLP and large branded food names can pass through inflation more reliably than XLY, RRGB or EAT. Elevated energy also creates a two-sided macro outcome: near-term nominal grocery sales may hold up, but persistent food inflation eventually shifts households toward private label, benefiting WMT, COST and KR more than branded suppliers.

Near-term, weak confidence alone is unlikely to change earnings estimates until retail sales, restaurant traffic and payroll data corroborate it. Over 1-3 months, the key catalyst is whether inflation expectations and energy prices force additional restrictive policy, lifting discount rates and compressing leveraged/small-cap multiples. The contrarian risk is that sentiment is a lagging survey measure: if employment remains resilient and energy retraces, oversold cyclicals and CHEF could outperform defensives despite poor headlines.

The article's analyst-rank framing is not independently sufficient to establish durable earnings power; prioritize revisions to revenue, gross margin, free cash flow and leverage rather than consensus EPS changes. This is a relative-value setup, not a broad risk-off signal, unless hard activity data deteriorate alongside credit spreads.

Key Decisions for Investors

• Initiate a 1-3 month pair: long XLP / short XLY, sized beta-neutral. Target 5-8% relative outperformance if consumer spending and labor data soften; exit if core inflation cools materially and the next payroll report reaccelerates, or if the relative spread breaks below the pre-entry low.
• Avoid treating CHEF as a defensive long. Use a sub-3 month short/watch position only after confirmed negative restaurant traffic or a guidance cut; a 10-15% downside is plausible on restaurant-volume deleveraging, but cover on sustained same-customer-sales resilience or a material food-cost deflation tailwind.
• Prefer WMT or COST over DOLE for a defensive consumer allocation over 6-12 months: both are better positioned for trade-down and private-label share gains. DOLE becomes more attractive only if freight/energy costs decline and management demonstrates gross-margin preservation rather than merely stable produce volumes.
• Keep BHC as a tactical, not core, healthcare exposure. Require evidence of free-cash-flow conversion and debt reduction at the next results before adding; a rise in financing costs, weaker deleveraging guidance, or refinancing stress falsifies the defensive thesis.
• Do not initiate CDNA solely on macro weakness or estimate revisions. Set an alert for reimbursement coverage changes, transplant-test volume growth and cash-burn trajectory; absent those data, its company-specific downside can dominate any defensive-healthcare factor exposure.